MoonLake Immunotherapeutics Faces Class Action for Misleading Statements During Trial Period

Written by Emily J. Thompson, Senior Investment Analyst

MLTX-2.57%

Source: Globenewswire

Updated: Nov 28 2025

0mins

Source: Globenewswire

Class Action Initiation: The DJS Law Group alerts investors of a class action lawsuit against MoonLake Immunotherapeutics for false statements made between March 10, 2024, and September 29, 2025, with a deadline for participation set for December 15, 2025.
False Statement Allegations: The complaint alleges that MoonLake misrepresented its sonelokimab drug as superior to competing therapies without proven advantages, leading to significant investor losses when the Phase 3 trial results were deemed “disastrous.”
Investor Rights Protection: Affected shareholders are encouraged to register for participation in the case, and upon registration, they will receive status updates through portfolio monitoring software, ensuring they remain informed throughout the case lifecycle.
Legal Team Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, attracting attention from major hedge funds and alternative asset managers worldwide.

MLTX

$16.33+Infinity%1D

Analyst Views on MLTX

Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 24.10 USD with a low forecast of 5.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Analyst Rating

9 Buy

2 Hold

1 Sell

Moderate Buy

Current: 16.760

Low

5.00

Averages

24.10

High

45.00

Current: 16.760

Low

5.00

Averages

24.10

High

45.00

BTIG

Neutral -> Buy

upgrade

$24

Al Analysis

2026-01-09

Reason

BTIG

Price Target

$24

Al Analysis

2026-01-09

upgrade

Neutral -> Buy

Reason

BTIG upgraded MoonLake Immunotherapeutics to Buy from Neutral with a $24 price target. The firm cites yesterday's regulatory update for the upgrade. A Type B meeting with the FDA confirmed that MoonLakecould establish substantial evidence of effectiveness of SLK in hidradenitis suppurativa without conducting additional clinical studies, the analyst tells investors in a research note. BTIG says this "positive update clears a significant overhang" for MoonLake's clinical development and could position SLK to receive FDA approval.

H.C. Wainwright

Buy

maintain

$26 -> $32

2026-01-09

Reason

H.C. Wainwright

Price Target

$26 -> $32

2026-01-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $32 from $26 and keeps a Buy rating on the shares. The company's FDA Type B meeting outcome delineates a path to registration, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MLTX

Unlock Now

Clear Street

NULL -> Buy

upgrade

$12 -> $45

2026-01-08

Reason

Clear Street

Price Target

$12 -> $45

2026-01-08

upgrade

NULL -> Buy

Reason

Clear Street raised the firm's price target on MoonLake Immunotherapeutics to $45 from $12 and keeps a Buy rating on the shares after company's Type B FDA meeting confirmed that no additional clinical trials are required and the current dataset is sufficient for a BLA submission and to establish sonelokimab's substantial evidence of effectiveness. There is a path to a "compelling label" with Mira efficacy results included alongside the Vela trials, the analyst tells investors.

Cantor Fitzgerald

Prakhar Agrawal

Overweight

maintain

2025-12-04

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

2025-12-04

maintain

Overweight

Reason

STAT reports that the FDA plans to shift toward requiring only one pivotal trial for approval rather than the traditional two, though details and timing remain unclear pending formal agency communication, Cantor Fitzgerald analyst Prakhar Agrawal tells investors in a research note. While the policy could have broad sector implications, it meaningfully boosts the likelihood of MoonLake's sonelokimab securing hidradenitis suppurativa approval based on a single positive pivotal study, the analyst says. Cantor has an Overweight rating on MoonLake shares.

About MLTX

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.